ALPS Advisors’s Medicines Co MDCO Stock Holding History

ALPS Advisors’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-78,098	Closed	-$2.48M	–	648
2016 Q1	$2.48M	Sell	78,098 -13,384	-15%	-$437K	0.03%	145
2015 Q4	$3.42M	Sell	91,482 -13,027	-12%	-$492K	0.03%	144
2015 Q3	$39.7K	Buy	104,509 +38,784	+59%	+$1.36M	0.04%	127
2015 Q2	$1.88M	Buy	65,725 +33,199	+102%	+$925K	0.02%	173
2015 Q1	$911K	Buy	+32,526	New	+$914K	0.01%	188

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's MDCO Position: Q2 2016 in Review

ALPS Advisors sold out of Medicines Co (MDCO) in Q2 2016, closing a stake of 78,098 shares — an estimated $2.48M sold.

ALPS Advisors first reported a position in MDCO in Q1 2015 and held it in 5 quarters. The position peaked at $3.42M in Q4 2015. 190 funds tracked by Wall St. Rank hold MDCO as of Q2 2016.

ALPS Advisors reported no remaining Medicines Co position as of Q2 2016 after selling out during the quarter.
ALPS Advisors sold 78,098 Medicines Co shares in Q2 2016, an estimated $2.48M.
ALPS Advisors first reported a position in Medicines Co in Q1 2015 and held it in 5 quarters.
ALPS Advisors's Medicines Co position peaked at $3.42M in Q4 2015.
190 funds tracked by Wall St. Rank held Medicines Co as of Q2 2016.

Based on ALPS Advisors's 13F filing for Q2 2016, filed 27 Jul 2016.